Radiotherapy of high-grade gliomas: Current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches

Chinese Journal of Cancer

Volumn 33, Issue 1, 2014, Pages 16-24

  Dhermain, Frederic ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Advanced imaging; High grade gliomas; MRI; PET; Radiotherapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB;

ANGIOGENESIS; ARTICLE; BLOOD VOLUME; CELL DENSITY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; GLIOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION DOSE ESCALATION; RADIOSENSITIVITY; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DIFFUSION TENSOR IMAGING; GLIOBLASTOMA; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NEOPLASM GRADING; PARTICLE ACCELERATORS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84891684715     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10217     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005,352:987-996.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007,114:97-109.
3. Kelly PJ, Daumas-Duport C, Kispert DB, et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg, 1987,66:865-874.
4. Price SJ, Gillard JH. Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol, 2011,84:S159-S167.
5. Chinnaiyan P, Won M, Wen PY, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys, 2013,86:880-884.
6. EORTC trials: www.groups.eortc.be/brain/html/trials.html.
7. Minniti G, Amelio D, Amichetti M, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol, 2010,97:377-381.
8. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer, 1991,64:769-774.
9. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys, 2004,60:853-860.
10. Nieder C, Mehta MP. Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma. Med Hypotheses, 2011,76:410-413.
11. Petrecca K, Guiot MC, Panet-Raymond V, et al. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol, 2013,111:19-23.
12. Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res, 2012,18:273-279.
13. Piroth MD, Pinkawa M, Holy R, et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol, 2012,188:334-339.
14. Viel T, Talasila KM, Monfared P, et al. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI. J Nucl Med, 2012,53:1135-1145.
15. Isambert A, Dhermain F, Bidault F, et al. Evaluation of an atlas-based automatic segmentation software for the delineation of brain organs at risk in a radiation therapy clinical context. Radiother Oncol, 2008,87:93-99.
16. Metcalfe P, Liney GP, Holloway L, et al. The potential for an enhanced role for MRI in radiation-therapy treatment planning. Technol Cancer Res Treat, 2013,12:429-446.
17. Holdsworth CH, Corwin D, Stewart RD, et al. Adaptive IMRT using a multiobjective evolutionary algorithm integrated with a diffusion-invasion model of glioblastoma. Phys Med Biol, 2012,57:8271-8283.
18. Neal ML, Trister AD, Ahn S, et al. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res, 2013,73:2976-2986.
19. Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol, 2007, 28:455-461.
20. McKnight TR, Lamborn KR, Love TD, et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg, 2007,106:660-666.
21. 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol, 2013,15:1058-1067.
22. Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys, 2001,50:915-928.
23. Narayana A, Chang J, Thakur S, et al. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. Br J Radiol, 2007,80:347-354.
24. Dhermain F, Saliou G, Parker F, et al. Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. J Neurooncol, 2010,97:81-88.
25. Jain R, Narang J, Griffith B, et al. Prognostic vascular imaging biomarkers in high-grade gliomas: tumor permeability as an adjunct to blood volume estimates. Acad Radiol, 2013,20:478-485.
26. Hu LS, Eschbacher JM, Heiserman JE, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol, 2012,14:919-930.
27. Meyzer C, Dhermain F, Ducreux D, et al. A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI. Radiat Oncol, 2010,5:9.
28. Ducreux D. Statistical analysis of multi b factor diffusion weighted images can help to distinguish between vasogenic and tumor-infiltrated edema. J MRI, 2013 Nov 4. DOI: 10.1002/jmri.24399.
29. Matsuo M, Miwa K, Tanaka O, et al. Impact of [11C] methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys, 2012,82:83-89.
30. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med, 2005,46:1948-1958.
31. Price SJ, Fryer TD, Cleij MC, et al. Imaging regional variation of cellular proliferation in gliomas using 3'-deoxy-3'-[18F]fluoro-thymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol, 2009,64:52-63.
32. Niyazi M, Geisler J, Siefert A, et al. FET-PET for malignant glioma treatment planning. Radiother Oncol, 2011,99:44-48.
33. Rieken S, Habermehl D, Giesel FL, et al. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol, 2013, 109:487-492.
34. Jain R, Poisson L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology, 2013,267:212-220.
35. Galbán CJ, Chenevert TL, Meyer CR, et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res, 2011,17:4751-4760.
36. Lee IH, Piert M, Gomez-Hassan D, et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2009,73:479-485.
37. Piroth MD, Holy R, Pinkawa M, et al. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol, 2011,99:218-224.
38. Dhermain FG, Hau P, Lanfermann H, et al. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol, 2010,9:906-920.
39. Weber MA, Henze M, Tüttenberg J, et al. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas? Invest Radiol, 2010,45:755-768.
40. Narayana A, Kunnakkat SD, Medabalmi P, et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys, 2012,82:77-82.
41. Gevaert T, Verellen D, Tournel K, et al. Setup accuracy of the Novalis ExacTrac 6DOF system for frameless radiosurgery. Int J Radiat Oncol Biol Phys, 2012,82:1627-1635.
42. Marsh JC, Godbole R, Diaz AZ, et al. Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study. J Med Imaging Radiat Oncol, 2011,55:442-449.
43. Marsh JC, Ziel GE, Diaz AZ, et al. Integral dose delivered to normal brain with conventional intensity-modulated radiotherapy (IMRT) and helical tomotherapy IMRT during partial brain radiotherapy for high-grade gliomas with and without selective sparing of the hippocampus, limbic circuit and neural stem cell compartment. J Med Imaging Radiat Oncol, 2013,57:378-383.
44. Einstein DB, Wessels B, Bangert B, et al. Phase II trial of radiosurgery to magnetic resonance spectroscopy-defined high-risk tumor volumes in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 2012,84:668-674.
45. Ken S, Vieillevigne L, Franceries X, et al. Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. Radiat Oncol, 2013,8:1.
46. Narayana A, Perretta D, Kunnakkat S, et al. Invasion is not an independent prognostic factor in high-grade glioma. J Cancer Res Ther, 2011,7:331-335.
47. Kil WJ, Tofilon PJ, Camphausen K. Post-radiation increase in VEGF enhances glioma cell motility in vitro. Radiat Oncol, 2012,7:25.
48. Bean J, Flament J, Ruyskart P, et al. The European Organisation for Research and Treatment of Cancer Imaging Programme. Eur Oncol, 2010,6:92-95.
49. Weiler M, Pfenning PN, Thiepold AL, et al. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene, 2013,32:1099-1109.
50. Shah NJ, Oros-Peusquens AM, Arrubla J, et al. Advances in multimodal neuroimaging: hybrid MR-PET and MR-PET-EEG at 3 T and 9.4 T. J Magn Reson, 2013,229:101-115.